The purpose of our study was to characterize tissue factor pathway inhibitor (TFPI) release from human vascular endothelial cells following daily exposure to varying concentrations of unfractionated heparin (UFH) and low molecular weight heparin (LMWH).
T he early management of patients with non-ST segment elevation acute coronary syndromes (ACS) includes a strategy of anticoagulant therapy, a recommended practice based on the well characterized contribution of coagulation proteases to thrombus growth and development in atherosclerotic vascular disease [1] . Several observations made during the past decade, citing enhanced thrombin generation [2] and recurrent coronary arterial thrombotic events [3] shortly after the abrupt discontinuation of unfractionated heparin (UFH), support the existence of an acquired thrombophilic state. Our group has reported [4] that thrombin generation begins within one (1) hour of UFH cessation, increases progressively (by nearly 2-fold) over the subsequent 24 hours, and correlates inversely with plasma concentrations of tissue factor pathway inhibitor (TFPI).
Human TFPI is a modular protein composed of three Kunitz-type domains flanked by peptide fragments [5] . The K 1 domain inhibits factor VIIa complexed to tissue factor, while the K 2 domain inhibits factor Xa-a pivotal enzyme in the prothrombinase complex which converts prothrombin to thrombin [6] . No direct protease activity has been identified for the K 3 domain; however, it does contain a heparin binding site. Under physiologic conditions, the primary site for TFPI synthesis is within vascular endothelial cells, whereupon release and co-localization with surface glycosaminoglycans it contributes substantially to intrinsic thromboresistance [7, 8] . Vascular endothelial cells found within the human heart express the largest quantity of TFPI mRNA [9] ; a response mediated by physiologic demands and other stimuli that include shear stress [10] , thrombin [11] , activated monocytes [12] and exogenous heparin administration [13] .
Because anticoagulant therapy is commonly administered for several days in ACS and low molecular weight heparins (LMWH) are being utilized with increased frequency, we performed a study to characterize TFPI release and reserve from human vascular endothelial cells following prolonged periods of heparin exposure.
Methods

Endothelial cell cultures
Human umbilical vein endothelial cells (HUVEC) were obtained form Clonetics Inc. (lot #AF2053) and served as the model system. The cell line has been reported to show biomarkers expected for endothelial cells (factor VIII, Weibel-Palade bodies, and surface specific molecules),
The cells were grown in plastic tissue flasks containing medium MCDB 131 supplemented with 20% FBS, 6 µg/ml BBE and 2 mM glutamine at 37
• C in a humidified atmosphere of 95% oxygen and 5% CO 2 .
Endothelial cell TFPI release
The HUVEC cells were seeded on 24-well polystyrene culture dishes precoated with gelatin [14] in medium MCDB 131 at a density of 1.0 × 10 5 cells per dish. The cells were incubated to 100% confluence, washed with PBS (X2), relayered with culture medium and exposed to experimental procedures as follows: 
Results
Endothelial cell RFPI release
The release of TFPI from vascular endothelial cells in response to UFH, dalteparin and rEGF is shown in Figs. 1 and 2 .
In low concentrations (0.5 U/ml), UFH caused a progressive increase in TFPI concentrations with a peak level of 6.36 ± 0.51 ng/10 5 cells at 24 hours. TFPI was higher than control values (mean 0.9 ± 0.25 ng/10 5 cells) at 1, 8, 24 and 48 hours ( p < .0001); however, by 72 hours of daily UFH exposure, the values declined and were significantly below control at 144h ( p = 0.002), 168 hours ( p = 0.005) and following stimulation with rEGF (peak effect 1.93 ± 0.42 vs 4.3 ± 0.78, p = 0.001). The observed responses in TFPI release with high UFH concentrations (5 U/ml) were similar to those with low concentrations with several exceptions. TFPI levels were higher at 1 and 24 hours ( p = 0.009) following exposure to high compared with low concentrations of UFH. In addition, the rate of decline from peak levels at 24 hours over the subsequent 24 (23% vs 37% decline) and 48 (65% vs 70% decline) hours was greater with high concentrations compared with low concentration of heparin.
Dalteparin in low concentrations (1 U/ml) was associated with a steady increase in TFPI release with peak levels of 4.58 ± 0.59 ng at 24 hours. TFPI levels exceeded those of control at all sampling time points up to 120 hours ( p < 0.001). The differences were not statistically significant at 144 h, 168 h, or following stimulation with rEGF. As with UFH, dalteparin in high concentrations (5 U/ml) elicited a more robust TFPI release at several early time points (1, 48 and 72 hours [ p < 0.01]); however, beyond 72 hours there was a rapid decline in TFPI with significantly lower levels (compared with low concentration dalteparin exposure) at 96 and 120 hours ( p < 0.01).
Fig. 1. Tissue Factor Pathway Inhibitor (TFPI) release from human umbilical vein endothelial cells (HUVEC) with daily exposure to low concentrations of unfractionated heparin (UFH) and dalteparin. Cellular reserve was evaluated following incubation with recombinant epidermal growth factor (rEGF). TFPI release was greater with dalteparin than UFH by 72 hours of exposure and cellular reserve was maintained.
Fig. 2. Tissue Factor Pathway Inhibitor (TFPI) release following daily exposure to high concentrations of unfractionated heparin and dalteparin. As with low concentrations, TFPI release was greater with dalteparin than UFH by 72 hours of exposure; however, the overall proportional decrease in TFPI release over time was more robust at high compared to low concentrations for both heparin preparations.
UFH and dalteparin in low concentrations influenced TFPI differently. Although both yielded peak concentrations at 24 hours, UFH stimulated greater release at 1, 8 and 24 hours than dalteparin (all p < 0.001); however, by 72 hours the patterns were reversed, with endothelial cells exposed to dalteparin consistently releasing a 2-fold greater amount of TFPI than those incubated with UFH. This dichotomous pattern coupled with a greater release of TFPI following stimulation with rEGF in dalteparin-exposed cells supports a state of relative TFPI depletion following prolonged exposure to UFH. This hypothesis is supported further by the rapid proportional decrease of TFPI concentrations with UFH as compared to dalteparin exposed cells in the 24 to 48 hours following peak levels, exhibiting rates of decline of 23% and 65% versus 11% and 31%, respectively. A similar dichotomous release pattern and preserved cellular responsiveness to growth factor provocation was observed comparing high concentrations of UFH and dalteparin.
Discussion
Heparin administration, although recommended in the early management of patients with ACS is associated with a modest reduction in clinical events during treatment and a clustering of ischemicthrombotic episodes following its discontinuation. Initially, UFH provokes TFPI release from vascular endothelial cells to a greater degree than LMWH dalteparin; however, with daily exposure, cellular reserve and responsiveness are compromised more profoundly with UFH. An acquired state of impaired thromboresistance to tissue factor may contribute to both treatment failure and the heparin "rebound" phenomenon after prolonged periods of heparin administration.
Clinical and biochemical evidence of heparin rebound
The initial description of heparin rebound can be attributed to Théroux and colleagues [3] . In a landmark study of pharmacologic management [15] , 403 patients with ACS who had received either intravenous UFH, aspirin, both, or neither for at least 6 days were followed closely after treatment discontinuation for clinical events including reactivation of unstable angina or myocardial infarction. A clustering of events (mean 9.5 hours after treatment) occurred in 14 of 107 patients who had received UFH alone, as compared with only 5 patients in each of the other three study groups. The GUSTO IIb study included a total of 12,142 patients who received either UFH or recombinant hirudin (desirudin) for 76 to 120 hours. From a cohort of 8,943 patients, 215 (2.4%) suffered an MI following discontinuation of study drug-49 patients within 12 hours of treatment and 166 patients between 12 hours and hospital discharge. The rate of early/recurrent MI was significantly higher among patients given UFH than hirudin (0.8% versus 0.3%), p = 0.002) and was associated with higher 30 day and 1 year mortality [16] . The rates of death, MI and refractory angina were particularly high during the initial 24 hours following cessation of UFH among patients participating in the TRIM study [17] . In PURSUIT [18] there was a 2.5-fold increase of death or myocardial (re) infarction within 12 hours of UFH discontinuation.
Although clinical "rebound" has been reported less frequently following treatment with LMWH several studies suggest that it does indeed occur. In the FRISC study [19] a trend toward increased events was observed after a reduction in dalteparin dose and following cessation of treatment. The initial benefit achieved during 4 to 6 weeks of treatment in FRISC II [20] dissipated over time. A reduced incidence of rebound with LMWH compared to UFH is supported; however, by the ESSENCE ST-segment monitoring substudy [21] . Recurrent ischemia following drug discontinuation occurred more frequently in patients treated with UFH than those given enoxaparin (46% vs 18%) and also portended a poor prognosis.
Whether the observed clustering of events following UFH therapy cessation represents a removal of suppression (of an underlying prothrombotic environment existing in a relatively quiescent state during treatment) [22, 23] or a true "rebound" phenomenon remains a question of considerable interest and clinical relevance. Granger and colleagues [2] observed transient but significant thrombin generation within 3 to 6 hours of UFH cessation. The OASIS investigators [24] reported a significant increase in thrombin generation and activity 6 hours following cessation of UFH. Our group has shown that patients with coronary artery disease exhibit heightened thrombin generation [25] that persists despite treatment with UFH [26] and increases further within 1 hour of treatment discontinuation [4] . We also observed attenuated post-treatment thrombin generation in patients with ACS using a strategy of intravenous UFH weaning, suggesting the presence of one or more modifiable pathways of thrombin generation.
The Importance of Tissue Factor and its Regulation
The relative thrombogenicity of atheromatous plaques, dysfunctional endothelial cells, and circulating cellular components is influenced strongly by tissue factor, an integral membrane glycoprotein containing 263 amino acids that complexes with factor VII, facilitating its activation (factor VIIa) and factor Xa-mediated conversion of prothrombin to thrombin. Work performed in our laboratory (Li Y, unpublished data) also show that the tissue factorVIIa complex activates factors IX and VIII (coagulation pathway cross-talk). Plaque disruption leads to release of membrane-bound active tissue factor (lipid containing microparticles with procoagulant activity) [27] . Patients with ACS demonstrate high concentrations of tissue factor antigen and activity [28] within tissue specimens obtained by coronary atherectomy, and there is evidence that monocytes express tissue factor after ischemic injury [29] . In addition, vascular endothelial cells are able to synthesize tissue factor following stimulation with endotoxin, interleukin 1, tumor necrosis factor and thrombin [30] [31] [32] [33] .
The tissue factor-VIIa complex is regulated on the endothelial cell surface by TFPI and antithrombin. In addition to neutralizing the enzymatic activity of tissue factor-VIIa, TFPI also promotes its internalization and cellular degradation [34] . The relationship between TFPI and antithrombin is particularly important in maintaining vascular thromboresistance. Like TFPI, antithrombin inhibits tissue factor-VIIa complexes; both work in concert to inhibit prothrombinase activity (and thrombin generation) on cell surfaces [35] . Furthermore, TFPI augments antithrombin by decreasing the rate of prothrombinase activity, enabling antithrombin to inhibit factors IXa and Xa [36] . Expression of TFPI in vivo has been shown to suppress thrombin formation in stenotic and injured rabbit carotid arteries, supporting the pivotal roles of tissue factor, factor VIIa and factor Xa in arterial thrombosis [37] . It also down-regulates production of tissue factor on mononuclear cells [5] .
The administration of UFH in vivo causes a prompt mobilization of TFPI into the circulation, increases its specific activity, and prolongs the serine proteases plasma half-life. Although the mechanism was originally thought to be a displacement of TFPI from membrane heparan sulfate proteoglycan (syndecans and glypicans) surface binding sites [38] , more recent evidence indicates secretion from intracellular storage pools. Hanson and colleagues [39] found that endothelial cells exposed to heparin released TFPI into the tissue culture medium without a change in surface membrane TFPI. Northern blot analysis revealed two mRNA transcripts (a 4 kb and 1.4 kb species) for TFPI expressed within 10 minutes of UFH exposure, peaking at 2 to 4 hours. In our study, TFPI concentrations increased steadily over the initial 24 hours, but then declined to below those of control with continued UFH exposure (time-dependent phenomenon). Furthermore, TFPI release in response to rEGF stimulation was attenuated, supporting either depletion of intracellular storage pools or reduced synthetic capacity. Independent of responsible mechanisms, the existence of a "recruitable" TFPI pathways suggests that vascular surface inhibition of tissue factor occurs in several escalating stages commensurate with the intensity and/or duration of prothrombotic stimuli. The provokable response to heparin preparations also appears to be dose (concentration)-dependent from several perspectives. First, a greater release of TFPI was elicited at high as compared to low concentrations of UFH. Second, the proportional decrease in TFPI from peak levels was more robust with high concentrations. Decreased intracellular TFPI following UFH exposure has been reported by several investigators [40, 41] , with an accompanying decline in tissue factor-mediated inhibitory potential. These observations are consistent with our findings among patients with ACS in whom thrombin generation occurring within several hours of UFH cessation correlated directly with factor VII activity and inversely with TFPI concentration [4] . They are also in keeping with clinical observations wherein UFH, infused for 72 hours or more has led to an increased rate of ischemic/thrombotic events within several hours of its discontinuation [15] [16] [17] [18] .
We postulate that UFH administered for several days reduces endothelial cell TFPI concentrations, impairing vascular thromboresistance to tissue factor. A proportional decrease in TFPI concentration accompanies heparin clearance [4, 13, 42] . Thus, there is a steadily declining "tissue factor inhibiting capacity" that occurs during UFH treatment (paralleled by decreased antithrombin activity) which dissipates further for several hours after drug discontinuation. An accompanying consumption of TFPI through neutralization of factors VIIa and Xa generated from unstable atheromatous plaques [43, 44] and reduced protein C activation [45] would further shift the balance of coagulation (thrombosis) and anticoagulation unfavorably, particularly for the initial several hours following termination of anticoagulant therapy when thrombotic stimuli often persist and both TFPI and antithrombin-mediated thromboresistance have not yet been restored to full capacity. The potential contribution of poorly regulated tissue factor expression on mononuclear cells following prolonged heparin exposure has not yet been elucidated [5] .
The cellular sequence of events with LMWH differs from that of UFH, at least with regard to the amount of TFPI released (peak effect), rate of decline with continued exposure and responsiveness to provacative stimuli. The current observations support those made in the context of clinical trials, wherein heparin rebound occurs less often [21] and may relate, at least in part, to charge density, molecular weight, antithrombin affinity and vascular endothelial cell binding capacity [46] [47] [48] [49] [50] .
Conclusions
Unfractionated heparin, and to a lesser degree dalteparin, a LMWH preparation, stimulate TFPI release from human vascular endothelial cells. With daily exposure cellular reserve and responsiveness decline, particularly with UFH. An acquired state of impaired vascular thromboresistance to tissue factor may develop with prolonged administration of UFH and contribute directly to treatment failures and thrombotic events following drug cessation among patients with ACS.
